CompletedPhase 3NCT00002459
Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus
Studying Carcinosarcoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- Sergio L. Pecorelli, MDSpedali Civili di Brescia
- Intervention
- radiation therapy(radiation)
- Enrollment
- 224 enrolled
- Eligibility
- FEMALE
- Timeline
- 1988
Study locations (28)
- U.Z. Gasthuisberg, Leuven, Belgium
- Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada
- CHUS-Hopital Fleurimont, Fleurimont, Quebec, Canada
- Centre Henri Becquerel, Rouen, France
- Spedali Civili, Brescia, Italy
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
- Istituto Scientifico H.S. Raffaele, Milan, Italy
- Ospedale San Gerardo, Monza, Italy
- Universita di Padova, Padua, Italy
- I.R.C.C.S. Policlinico San Matteo, Pavia, Italy
- Ospedale di Circolo e Fondazione Macchi, Varese, Italy
- Ospedale Civile, Voghera (PV), Italy
- Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands
- Antoni van Leeuwenhoekhuis, Amsterdam, Netherlands
- Medisch Spectrum Twente, Enschede, Netherlands
- +13 more locations on ClinicalTrials.gov
Collaborators
NCIC Clinical Trials Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00002459 on ClinicalTrials.govOther trials for Carcinosarcoma of the corpus uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07029399A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNiKang Therapeutics, Inc.
- RECRUITINGPHASE2NCT05619913EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaAustralia New Zealand Gynaecological Oncology Group
- ACTIVE NOT RECRUITINGPHASE2NCT05147558A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsImmatics US, Inc.